ZA202001472B - Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics - Google Patents

Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Info

Publication number
ZA202001472B
ZA202001472B ZA2020/01472A ZA202001472A ZA202001472B ZA 202001472 B ZA202001472 B ZA 202001472B ZA 2020/01472 A ZA2020/01472 A ZA 2020/01472A ZA 202001472 A ZA202001472 A ZA 202001472A ZA 202001472 B ZA202001472 B ZA 202001472B
Authority
ZA
South Africa
Prior art keywords
mimetics
compositions
methods
lysine analogs
synthetic lysine
Prior art date
Application number
ZA2020/01472A
Other languages
English (en)
Inventor
Frank Murdock
Ronnea Murdock
W Paul Stewart
Original Assignee
Anti Viral Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anti Viral Tech Llc filed Critical Anti Viral Tech Llc
Publication of ZA202001472B publication Critical patent/ZA202001472B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2020/01472A 2017-08-27 2020-03-09 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics ZA202001472B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US201862664555P 2018-04-30 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Publications (1)

Publication Number Publication Date
ZA202001472B true ZA202001472B (en) 2022-05-25

Family

ID=65525881

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/01472A ZA202001472B (en) 2017-08-27 2020-03-09 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Country Status (11)

Country Link
US (2) US11413279B2 (enExample)
EP (1) EP3672584A4 (enExample)
JP (3) JP2020531586A (enExample)
KR (1) KR102706114B1 (enExample)
CN (1) CN111315374A (enExample)
AU (2) AU2018324427B2 (enExample)
BR (1) BR112020003735A2 (enExample)
CA (1) CA3073685A1 (enExample)
MX (2) MX2020002156A (enExample)
WO (1) WO2019045989A1 (enExample)
ZA (1) ZA202001472B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156617A1 (en) * 2019-10-29 2021-05-06 W. Paul Stewart Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
WO2021162879A1 (en) * 2020-02-14 2021-08-19 Tranexamic Technologies, Llc Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs
JP2022132181A (ja) * 2021-02-26 2022-09-07 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789764B1 (en) * 1994-10-28 2002-01-09 Vitaleech Bioscience N.V. A novel family of protease inhibitors, and other biologic active substances
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) * 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
JP4600882B2 (ja) * 2002-10-11 2010-12-22 第一三共株式会社 抗インフルエンザウイルス剤
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
JP5730211B2 (ja) * 2008-11-20 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． ウイルスのアルギニン不活化
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN103405384B (zh) * 2013-09-01 2015-05-13 吴静 氨甲环酸的药物组合物

Also Published As

Publication number Publication date
MX2023009499A (es) 2023-08-23
CN111315374A (zh) 2020-06-19
KR102706114B1 (ko) 2024-09-11
JP2023123440A (ja) 2023-09-05
WO2019045989A1 (en) 2019-03-07
US11413279B2 (en) 2022-08-16
BR112020003735A2 (pt) 2020-09-01
AU2018324427A1 (en) 2020-04-09
KR20200052310A (ko) 2020-05-14
CA3073685A1 (en) 2019-03-07
EP3672584A4 (en) 2021-05-05
AU2018324427B2 (en) 2024-03-07
MX2020002156A (es) 2020-07-20
JP2020531586A (ja) 2020-11-05
EP3672584A1 (en) 2020-07-01
US20200323837A1 (en) 2020-10-15
AU2024203839A1 (en) 2024-06-27
US20220288050A1 (en) 2022-09-15
JP2025166032A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
IL275468A (en) Incretin analogs and their use
IL275469A (en) Incretin analogs and their use
IL273440A (en) Strengthening the effect of ATP release
IL254089A0 (en) Desacetoxytobulizin h and its analogs
IL287141A (en) Malassin and its analogues as skin lightening agents
IL273387A (en) Thylanstatin analogs
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL256553B (en) Cystamine analogs resistant to cysteamine oxygenase and their uses
IL268514A (en) Medical bacteriophage preparations
IL264403A (en) Vortioxetine analogue and use and preparation thereof
IL272857A (en) Cofanalisib formulations
IL265270A (en) Prostacyclin analog formulations
ZA202001472B (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
IL277466A (en) Formulations containing peptides
IL263155A (en) Combination formulation of three antiviral compounds
DK3573468T3 (en) Fat Composition
ZA201906326B (en) Analogs of deutetrabenazine, their preparation and use
GB201614961D0 (en) Compounds and compositions for use
GB201603591D0 (en) Improved promotors and compositions
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
PT3678644T (pt) Formulações de copanlisib
DK3582624T3 (en) Fat composition
EP3713604C0 (de) Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit
AP2017009770A0 (en) The game of gendaball
GB201702194D0 (en) Geopod 2 LRF